Introduction to Refractory Recurrent

What is/are Refractory Recurrent?

Refractory Recurrent - Conclusions In platinum-sensitive recurrent ovarian cancer, PLD plus carbo was more effective than PAC plus carbo, while in platinum-resistant or -refractory recurrent ovarian cancer, PLD exhibited similar survival to other monotherapies. ^[1] Here, we describe the outcome of the infusion of in vitro expanded CMV-reactive T-cells, taken from a healthy CMV-seropositive donor, in a liver-transplanted recipient with a refractory recurrent CMV. ^[2] We report on a patient with chemotherapy-refractory recurrent VCCC, who was found to have high tumor programmed death-ligand 1 (PD-L1) combined positive score (CPS), and subsequently experienced a durable partial response (PR), after treatment with off-label fifth-line pembrolizumab. ^[3] • VBT is a good clinical option for patients with refractory recurrent ISR in the DES era. ^[4] We report a case of 72-year-old male, with chronic alcohol abuse, presenting with atypical features like refractory recurrent secondary generalized seizures and behavioral disturbances with increased irritability, initially mistreated as alcohol withdrawal. ^[5] Current guidelines unfortunately reflect this inertia, as there is relative paucity of additional therapies for patients with refractory recurrent pericarditis Cardiovascular Imaging, Cleveland Clinic, Cleveland, Ohio, USA. ^[6] OBJECTIVE To evaluate the effectiveness of etanercept in the treatment of refractory recurrent spontaneous abortion with innate immune disorders. ^[7] 6073Background: Nivo, which inhibits the programmed death-1 (PD-1) receptor, improved survival for pts with platinum-refractory recurrent/metastatic HNSCC. ^[8] Anti-programmed cell death 1 (PD-1) therapies, currently approved for platinum-refractory recurrent and/or metastatic HNSCC, offer the prospect of long-term remissions with fewer toxicities than traditional cytotoxic chemotherapy for a minority of patients, and are expected to advance to earlier lines of therapy. ^[9] e17502Background: To evaluate the efficacy and safety of apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma. ^[10] Background Fecal microbiota transplantation (FMT) is now approved for the treatment of refractory recurrent clostridial colitis, but a number of studies are ongoing in inflammatory bowel diseases, i. ^[11] In this study we assessed the effectiveness, safety and feasibility of prophylactic treatment with intravesical gentamicin in patients with refractory recurrent urinary tract infections caused by multidrug resistant microorganisms. ^[12] Background: Refractory recurrent ventricular tachycardia is a difficult therapeutic problem. ^[13] Some subgroups of patients show refractory recurrent bleeding despite standard endoscopic therapy. ^[14] Nearly 10 years after the approval of cetuximab, anti-PD1/PD-L1 checkpoint inhibitors are the first drugs that have shown any survival benefit for the treatment on platinum-refractory recurrent/metastatic (R/M) HNSCC. ^[15] Objective To investigate the efficacy of thalidomide combined with DICE scheme in the treatment of refractory recurrent non-hodgkin lymphoma patients and the occurrence of toxic and side effects. ^[16] BackgroundFecal microbiota transplantation (FMT) has been recently approved by FDA for the treatment of refractory recurrent clostridial colitis (rCDI). ^[17] A patient with platinum-refractory recurrent oral cavity HNSCC underwent comprehensive genomic profiling (CGP) that identified an activating MET mutation (R1004). ^[18] We report a successful first birth case from a patient with refractory recurrent implantation failure (RIF) by using endometrial receptivity array (ERA) test in Japan. ^[19] Long half-life SST analogues are now recommended for the systemic treatment of unresectable or radiation-refractory recurrent human meningiomas. ^[20] Background To evaluate the efficacy and safety of apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma. ^[21] The prognosis of refractory recurrent RMS is extremely poor, and the 5-year survival rate is less than 20%. ^[22]

squamous cell carcinoma

Anti-programmed cell death protein 1 (PD-1) agents have become the standard of care for platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and are currently being evaluated in various disease settings. ^[1] ObjectivesIn the CheckMate 141 trial (NCT02105636), nivolumab demonstrated survival, health-related quality of life, and healthcare resource utilization benefits vs single-agent therapy of investigator’s choice (IC) (methotrexate, docetaxel or cetuximab) in patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). ^[2] 68Background: Nivolumab improved overall survival (OS) in the treatment of platinum-refractory recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) in a phase III clinical tri. ^[3] Background Nivolumab, approved in Japan for platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) in 2017, is of uncertain cost-effectiveness. ^[4]

metastatic squamous cell

In the Phase‐III clinical trial, CheckMate 141, nivolumab significantly improved survival versus standard of care in patients with platinum‐refractory recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). ^[1]

neck squamous cell

Key Points Question Is nivolumab or pembrolizumab more cost-effective for treatment of US patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma? Findings In this cost-effectiveness analysis that included 487 patients, when the willingness-to-pay threshold was $100 000 per quality-adjusted life-year, for patients weighing less than 72 kg, nivolumab (3 mg/kg administered biweekly) was considered cost-effective; otherwise, pembrolizumab was preferable. ^[1]

refractory recurrent clostridial

Background Fecal microbiota transplantation (FMT) is now approved for the treatment of refractory recurrent clostridial colitis, but a number of studies are ongoing in inflammatory bowel diseases, i. ^[1] BackgroundFecal microbiota transplantation (FMT) has been recently approved by FDA for the treatment of refractory recurrent clostridial colitis (rCDI). ^[2]